Clinical Trials Directory

Trials / Conditions / Pleural Mesothelioma

Pleural Mesothelioma

39 registered clinical trials studyying Pleural Mesothelioma12 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEvaluation of Skin Tests in Biotherapy Allergies
NCT06971848
University Hospital, AngersN/A
RecruitingA Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413
IDEAYA BiosciencesPhase 1
RecruitingThe Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
NCT06790082
Aalborg University HospitalPhase 2
Active Not RecruitingInduction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
NCT06155279
Istituto Oncologico Veneto IRCCSPhase 2
RecruitingA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369
7 Hills Pharma, LLCPhase 1 / Phase 2
Not Yet RecruitingStudy of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
NCT06416930
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
RecruitingA Study of MT027 in Patients with Pleural Malignant Tumors
NCT06726564
Suzhou Maximum Bio-tech Co., Ltd.Phase 1
RecruitingEvaluation of Response by FLT PET in Mesothelioma
NCT06410625
Ankara UniversityN/A
RecruitingTRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
NCT05628376
University College, London
RecruitingStudy of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable
NCT05930665
Sun Yat-sen UniversityPhase 2
RecruitingTTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
NCT05538806
NovoCure Ltd.
RecruitingINTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE
NCT07403630
Azienda Ospedaliero-Universitaria di ParmaN/A
TerminatedNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NCT05714553
NuCana plcPhase 1 / Phase 2
SuspendedA Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
NCT05337735
M.D. Anderson Cancer CenterPhase 2
UnknownMolecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma
NCT04823741
Hospices Civils de Lyon
TerminatedA Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Canc
NCT04914897
SanofiPhase 2
RecruitingA Beta-only IL-2 ImmunoTherapY Study
NCT05086692
Medicenna Therapeutics, Inc.Phase 1 / Phase 2
CompletedDuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04334759
PrECOG, LLC.Phase 3
UnknownProspective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
NCT05910112
University of Oxford
CompletedDose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
NCT04430842
Quadriga Biosciences, Inc.Phase 1
CompletedeRAPID: Online Symptom Reporting in Lung Cancer
NCT04324437
University of LeedsN/A
UnknownA Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
NCT05077111
Mohamed Reda AshourPhase 4
CompletedFrom Presentation to Diagnosis: Patterns of Pleural Effusion
NCT07449624
Mansoura University Hospital
TerminatedA Study of SGN-CD228A in Advanced Solid Tumors
NCT04042480
Seagen Inc.Phase 1
CompletedUsing a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
NCT04040231
Memorial Sloan Kettering Cancer CenterPhase 1
TerminatedMesothelioma Early Detection by VOCs
NCT04106973
Henry Ford Health System
CompletedPhase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
NCT02899195
PrECOG, LLC.Phase 2
CompletedWhey Protein Supplement in Combination With Physical Exercise and Nutrition Program
NCT02585362
Kantonsspital Winterthur KSWN/A
TerminatedA Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malign
NCT02707666
University of ChicagoPhase 1
UnknownInternational Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
NCT03210298
Sabine Rhode
UnknownA Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1
NCT02588131
Italian Network for Tumor Biotherapy FoundationPhase 2
CompletedTILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
NCT02414945
University Health Network, TorontoPhase 1 / Phase 2
CompletedPhase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
NCT01160458
National Cancer Institute (NCI)Phase 2
TerminatedPemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
NCT00895648
University Health Network, TorontoPhase 2
TerminatedTrimodal Lung-Sparing Treatment of Pleural Mesothelioma
NCT00859495
Columbia UniversityPhase 2
CompletedGene Therapy for Pleural Malignancies
NCT00299962
University of PennsylvaniaPhase 1
TerminatedPleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thios
NCT00165503
Dana-Farber Cancer InstitutePhase 2
CompletedExtrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine
NCT00165516
Dana-Farber Cancer InstitutePhase 2
CompletedPleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mes
NCT00165555
Dana-Farber Cancer InstitutePhase 1